Fund moves
217KShares reported
From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BCTX · NASDAQ · Pharmaceutical Preparations
Briacell Therapeutics (BCTX) · oqro.io/stocks/BCTX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$3.06−0.10 (−3.16%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Briacell Therapeutics was filed in the last 90 days. The latest on record was on May 14, 2024.
Since 2022, Briacell Therapeutics insiders reported 3 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2024.
No open-market sale by an insider of Briacell Therapeutics (BCTX) was filed with the SEC in the last 90 days.
No trade in Briacell Therapeutics (BCTX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−56.4% (−$3.96) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $7.02 on Nov 20, 2025 to $3.06 on Nov 20, 2026 (−56.4%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 1 13F position change for 1 quarter ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in West Vancouver, A1.
Last 12 months
−56.4%
Market value
$26.7M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 808K shares sold short (9.2% of shares outstanding), +2.3% vs the previous count, 12.5 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Fund moves
From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
No Schedule 13D or 13G filing on BCTX over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Revenue
—
Free cash flow, last 12 months
−$5.96M
This quarter −$5.96M
Net debt
—
Debt —, cash $9.85M, at Jul 31, 2026
Net income, last 12 months
−$34.9M
Operating loss: profit did not cover interest (latest fiscal year)
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 28, 2022.
Insiders of Briacell Therapeutics reported 3 open-market purchases and 0 sales since 2022; purchases in 2 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $2M1×1 trade | — |
| 2022 | $246K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 3,000 words.
BriaCell is a clinical-stage biotechnology company that is developing novel immunotherapies to transform cancer care. Immunotherapies have come to the forefront in the fight against cancer as they harness the body’s own immune system to recognize and destroy cancer cells. The Company is currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer (listed on ClinicalTrials.gov as NCT06072612). Bria-IMT™ is currently under Fast Track Designation by the U.S. Food and Drug Administration (the “FDA”) intended to accelerate the review process of novel treatments that address unmet medical needs.
Source: SEC EDGAR, Form 10-K filed Oct 28, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
1 active phase 3 trial and 0 active phase 2 trials led by this company, mostly in breast cancer. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Latest annual report filed Oct 28, 2026, compared with the one filed Oct 16, 2025. Read the filing
We may be involved from time to time in ordinary litigation, negotiation, and settlement matters that will not have a material effect on our operations or finances. There are no material legal proceedings pending against the Company.
Source: SEC EDGAR, Form 10-K filed Oct 28, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Off-exchange trading: 51.5% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (6.3% on ATS, 45.2% with other brokers), close to its 26-week average of 51.1%. Weeks of Sep 21 to Oct 16, 2026.
Things to keep in mind
Largest ATS: UBS ATS (16.3%), SIGMA X2 (15.0%), MS POOL (ATS-4) (14.8%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
On the public record for Briacell Therapeutics over the 12 months to Nov 21, 2026: 1 clinical trial.